Alliance Revenue (Tables)

12 Months Ended

Dec. 31, 2019

Schedule of accompanying statements of operations and comprehensive loss


(In thousands)	2019		2018		2017
Out-license arrangement (1)	$	1,447	$	—	$	—
GSK collaboration (2)		—		517		863
Vivelix collaboration (3)		—		56		14
Other (4)		1		89		25
Total Alliance revenue	$	1,448	$	662	$	902

(1)

For the year ended December 31, 2019, the Company recognized Alliance revenues of $1.4 million under the Licensee Agreement, as more fully described in Note 10, primarily related to the transfer of the IMO-8400 License and IMO-8400 drug product.

(2)

For the years ended December 31, 2018 and 2017, revenue recognized primarily relates to the amortization of the $2.5 million upfront, non-refundable, non-creditable cash payment received upon the execution of the GSK Agreement, as more fully described in Note 10, which was recognized as revenue on a straight-line basis over the estimated 36-month research plan period, which approximated the timing in which performance obligations were satisfied. No such revenue was recognized during 2019. Revenue recognized for the year ended December 31, 2017 also includes an additional $0.1 million related to additional research services performed in connection with the GSK Agreement.

(3)

For each of the years ended December 31, 2018 and 2017, revenue recognized relates to reimbursements for research services performed in connection with the Vivelix Agreement, as more fully described in Note 10.

(4)

For all periods presented, revenue recognized relates to collaborations which are not material to the Company’s current operations nor expected to be material in the future, including reimbursements by licensees of costs associated with patent maintenance.